Can-Fite Completes Patient Enrolment for Pivotal Psoriasis Study

Key Facts

In a move reflecting the accelerating pace of innovation within the dermatology biotech sector, Can-Fite BioPharma has announced the completion of enrolment for the first 247 patients in its pivotal Phase 3 study. This trial is designed to evaluate the efficacy and safety of Piclidenoson for the treatment of moderate-to-severe plaque psoriasis. The study is being conducted under a protocol agreed upon with the U.S. FDA and the European Medicines Agency (EMA) to ensure compliance with global regulatory standards.

This progress comes amid intense competition in the psoriasis market from major players like Amgen, which markets Otezla, as Piclidenoson seeks to provide an oral alternative with a distinct mechanism of action. According to industry reports, the global psoriasis treatment market is projected to grow at a CAGR of over 9%, reaching $53 billion by 2031 (per Allied Market Research). This milestone is viewed as a necessary step for Can-Fite to strengthen its competitive positioning against currently available biological and systemic therapies.

Operationally, investors are awaiting the interim analysis results of the study, with company estimates suggesting a final data readout may not occur until Q4 2026. Regarding the economic calendar, traders are monitoring the U.S. JOLTs Job Openings report on June 30, 2026, which could impact risk appetite for micro-cap biotech stocks. As updated price data for CANF is currently unavailable, market focus remains strictly on upcoming clinical catalysts and regulatory progress.